Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTICNASDAQ:CYTKNYSE:PBHNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/ACYTKCytokinetics$30.00-2.0%$39.42$29.93▼$61.40$3.58B0.811.67 million shs2.02 million shsPBHPrestige Consumer Healthcare$85.83-1.3%$83.16$62.35▼$90.04$4.25B0.44298,218 shs402,323 shsRYTMRhythm Pharmaceuticals$57.28+0.9%$57.30$35.17▼$68.58$3.64B2.36550,767 shs666,729 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTICCTI BioPharma0.00%0.00%0.00%0.00%0.00%CYTKCytokinetics-1.99%-9.20%-24.64%-27.92%-49.46%PBHPrestige Consumer Healthcare-1.28%+5.64%+4.51%+0.17%+20.17%RYTMRhythm Pharmaceuticals+0.86%-11.12%-4.76%-0.49%+41.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics4.0616 of 5 stars4.41.00.04.63.00.80.0PBHPrestige Consumer Healthcare3.5985 of 5 stars1.33.01.73.52.12.51.9RYTMRhythm Pharmaceuticals4.0869 of 5 stars4.51.00.04.32.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTICCTI BioPharma 0.00N/AN/AN/ACYTKCytokinetics 2.89Moderate Buy$74.44148.13% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.338.74% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$75.3831.61% UpsideCurrent Analyst Ratings BreakdownLatest CTIC, PBH, RYTM, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/7/2025CYTKCytokineticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/2/2025CYTKCytokineticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.005/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/24/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$55.004/21/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.004/15/2025CYTKCytokineticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$62.00 ➝ $54.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93CYTKCytokinetics$19.22M186.43N/AN/A($3.94) per share-7.61PBHPrestige Consumer Healthcare$1.14B3.74$5.04 per share17.03$36.10 per share2.38RYTMRhythm Pharmaceuticals$136.86M26.63N/AN/A$2.87 per share19.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/ACYTKCytokinetics-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%N/APBHPrestige Consumer Healthcare$209.34M$4.2920.1018.032.6919.13%12.36%6.39%N/ARYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%N/ALatest CTIC, PBH, RYTM, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTICCTI BioPharmaN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.21%N/A44.29%N/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTICCTI BioPharmaN/A1.271.26CYTKCytokinetics5.939.289.28PBHPrestige Consumer Healthcare0.563.682.20RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTICCTI BioPharma91.45%CYTKCytokineticsN/APBHPrestige Consumer Healthcare99.95%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCTICCTI BioPharma7.61%CYTKCytokinetics2.70%PBHPrestige Consumer Healthcare1.60%RYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableCYTKCytokinetics250119.43 million114.00 millionOptionablePBHPrestige Consumer Healthcare54049.54 million48.75 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableCTIC, PBH, RYTM, and CYTK HeadlinesRecent News About These CompaniesRhythm FY Net Y758.00M Vs Net Y477.00MMay 14 at 11:21 AM | marketwatch.comRhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramMay 14 at 8:00 AM | globenewswire.comIntegral Health Asset Management LLC Invests $8.40 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 14 at 6:17 AM | marketbeat.comNorthern Trust Corp Has $30.53 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 13 at 4:17 AM | marketbeat.comHC Wainwright Has Negative Estimate for RYTM Q2 EarningsMay 13 at 1:31 AM | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for RYTMMay 13 at 1:29 AM | americanbankingnews.com138,363 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Balyasny Asset Management L.P.May 12 at 4:34 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by The Manufacturers Life Insurance CompanyMay 12 at 3:45 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Crestline Management LPMay 11, 2025 | marketbeat.comAlgert Global LLC Reduces Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 11, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 8,515 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 10, 2025 | marketbeat.comBridgefront Capital LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 10, 2025 | marketbeat.comEarnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimatesMay 9, 2025 | uk.investing.comRhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comTudor Investment Corp ET AL Invests $853,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing EarningsMay 9, 2025 | americanbankingnews.comNeedham & Company LLC Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00May 9, 2025 | americanbankingnews.comRhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...May 8, 2025 | finance.yahoo.comMariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 8, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTIC, PBH, RYTM, and CYTK Company DescriptionsCTI BioPharma NASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Cytokinetics NASDAQ:CYTK$30.00 -0.61 (-1.99%) As of 05/14/2025 04:00 PM EasternCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Prestige Consumer Healthcare NYSE:PBH$85.83 -1.14 (-1.31%) As of 05/14/2025 03:48 PM EasternPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Rhythm Pharmaceuticals NASDAQ:RYTM$57.28 +0.49 (+0.86%) As of 05/14/2025 04:00 PM EasternRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
